Mikael Totterman

See Beyond the Surface. Qmetrics: Meeting the Promise of Medical Image Analysis. What do you see when you have an ACL tear? Or when you daughter suffers a concussion playing hockey? How does your mother look when diagnosed with Alzheimer’s? A Medical Image can see much more. MRI, X-Rays and CT capture the image of injury or disease from the inside and Qmetrics provides the view. As a trusted, worldwide leader in medical imaging analysis, Qmetrics has the capability to delve deeper into a medical image and detect abnormalities not easily visible to a human eye. Our proprietary software programs provide a unique look into the human body, transforming 2D MR images into colorful, 3D models of anatomic structures, which can be quantitated and manipulated for a greater understanding of disease and injury. AI and Machine Learning Qmetrics’ proprietary software has the deep learning capability that through AI can extract data and measurements, that, with enough data gathered, may predict disease progression or track therapeutic benefits of treatments. The end result is our software’s ability to develop biomarkers of disease onset and progression, as well as staging. This capability may also allow us to monitor therapy efficacy. The data mining and AI capabilities possible allow Qmetrics to delve even deeper into injuries or disease, seeing far beyond the surface of traditional knowledge. Qmetrics automated processes’ allow clients to more cost-efficiently determine therapeutic efficacy of their products and improve clinical trials with precise, reliable and measurable results. Qmetrics’ product line includes Kuvia3D® which is FDA cleared for the display and analysis of DICOM image data to facilitate 3D visualization of joint anatomy for planning surgical and non-surgical therapies. Co-founded by Dr. Saara Totterman and Dr. Jose Tamez-Peña, Qmetrics is based in Pittsford, NY and provides services internationally.

iCardiac Technologies was acquired by ERT in December, 2017. ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that our customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, we balance knowledge of what works with a vision for what’s next, so we can adapt without compromising standards. Powered by the company’s EXPERT® technology platform, our solutions enhance trial oversight, enable site optimization, increase patient engagement, and measure the efficacy of new clinical treatments while ensuring patient safety. Over the past four years, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs, and CROs have relied on ERT solutions in over 10,000 studies spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence. Follow ERT and learn how you can accelerate clinical development with confidence.

Perfecting the Sense of Sight. Clerio Vision is developing a revolutionary product platform for the global ophthalmic market, based on technology licensed from the University of Rochester. The company is in the process of developing and commercializing a portfolio of next generation products in contact lenses, myopia control and cataract surgery. The team is composed of serial entrepreneurs with multiple exits as well as ophthalmic industry veterans who pioneered a number of new ophthalmic technology categories. The products are currently in clinical development.

See Beyond the Surface. Qmetrics: Meeting the Promise of Medical Image Analysis. What do you see when you have an ACL tear? Or when you daughter suffers a concussion playing hockey? How does your mother look when diagnosed with Alzheimer’s? A Medical Image can see much more. MRI, X-Rays and CT capture the image of injury or disease from the inside and Qmetrics provides the view. As a trusted, worldwide leader in medical imaging analysis, Qmetrics has the capability to delve deeper into a medical image and detect abnormalities not easily visible to a human eye. Our proprietary software programs provide a unique look into the human body, transforming 2D MR images into colorful, 3D models of anatomic structures, which can be quantitated and manipulated for a greater understanding of disease and injury. AI and Machine Learning Qmetrics’ proprietary software has the deep learning capability that through AI can extract data and measurements, that, with enough data gathered, may predict disease progression or track therapeutic benefits of treatments. The end result is our software’s ability to develop biomarkers of disease onset and progression, as well as staging. This capability may also allow us to monitor therapy efficacy. The data mining and AI capabilities possible allow Qmetrics to delve even deeper into injuries or disease, seeing far beyond the surface of traditional knowledge. Qmetrics automated processes’ allow clients to more cost-efficiently determine therapeutic efficacy of their products and improve clinical trials with precise, reliable and measurable results. Qmetrics’ product line includes Kuvia3D® which is FDA cleared for the display and analysis of DICOM image data to facilitate 3D visualization of joint anatomy for planning surgical and non-surgical therapies. Co-founded by Dr. Saara Totterman and Dr. Jose Tamez-Peña, Qmetrics is based in Pittsford, NY and provides services internationally.

iCardiac Technologies was acquired by ERT in December, 2017. ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that our customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, we balance knowledge of what works with a vision for what’s next, so we can adapt without compromising standards. Powered by the company’s EXPERT® technology platform, our solutions enhance trial oversight, enable site optimization, increase patient engagement, and measure the efficacy of new clinical treatments while ensuring patient safety. Over the past four years, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, Biotechs, and CROs have relied on ERT solutions in over 10,000 studies spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly – and with confidence. Follow ERT and learn how you can accelerate clinical development with confidence.